Moving on to greener pastures.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I’m about 30 days off but I think you will see .20 to .25 next week.
Funny thing is his linked in profile still shows being employed at Eli Lilly.
https://www.linkedin.com/in/david-kendall
David Kendall
Vice President - Medical Affairs - Lilly Diabetes
Eli Lilly and Company University of Minnesota Medical School
Indianapolis, Indiana
500+connections
Experience
Eli Lilly and Company
Vice President - Global Medical Affairs - Lilly Diabetes
Company Name
Eli Lilly and Company
Dates EmployedJun 2014 – Present Employment Duration3 yrs 9 mos
LocationIndianapolis, Indiana
Eli Lilly and Company
Distinguished Medical Fellow - Global Medical Affairs - Lilly Diabetes
Company NameEli Lilly and Company
Dates EmployedJul 2011 – Jun 2014 Employment Duration3 yrs
Locationindianapolis, indiana area
American Diabetes Association
Chief Scientific and Medical Officer
Company NameAmerican Diabetes Association
Dates EmployedJul 2009 – Jul 2011 Employment Duration2 yrs 1 mo
LocationAlexandria, VA
The International Diabetes Center
Medical Director
Company NameThe International Diabetes Center
Dates EmployedMay 2008 – Sep 2009 Employment Duration1 yr 5 mos
Amylin Pharmaceuticals
Executive Director - Medical Affairs
Company NameAmylin Pharmaceuticals
Dates EmployedNov 2005 – Jun 2008 Employment Duration2 yrs 8 mos
I agee with Martin. It’s pointless at times on this board. But long-term the company is just going to be great. You can count on it.
David Kendall is the missing link to moving forward. Go out and check his credentials. Google his name on YouTube you’ll see no less than 20 different videos that he had provided over the last 10 years showing the depth of his experience in the diabetes field.
This is a very big higher. Will help us to monetize Afrezza properly.
Would love to see Mike make a 50,000 share purchase the next week or 10 days.
It would be also nice to see institutional ownership home. It’s about as low as any stock I have ever owned has been.
Well the question is when will we get back over $400. I would but next week
Not looking good. I was hoping after they got the CE Mark in Europe things would get better. But check may be running out of cash.
LinkedIn profile has not been updated. but interesting has he must have just left
Lilly
David Kendall
•
Vice President - Medical Affairs - Lilly Diabetes
Eli Lilly and Company
• University of Minnesota Medical School
Experience
Eli Lilly and Company
Vice President - Global Medical Affairs - Lilly Diabetes
Company Name
Eli Lilly and Company
Dates Employed
Jun 2014 – Present
Employment Duration
•3 yrs 9 mos
Location
Indianapolis, Indiana
Eli Lilly and Company
Distinguished Medical Fellow - Global Medical Affairs - Lilly Diabetes
Company Name
Eli Lilly and Company
Dates Employed
Jul 2011 – Jun 2014
Employment Duration
•3 yrs
Location
indianapolis, indiana area
Read more: http://mnkd.proboards.com/thread/9525/david-kendall-mannkind-medical-officer?page=2#ixzz56aSvdp51
David Kendall is a game changer. Go out and do the research you will find 15 to 20 videos he is done over the last 10 years on various topics regarding diabetes. Some of them while he was with Eli Lily, some of them when he was with the ADA. Others were with different organizations. The one thing you will find is it he is a very consummate professional who understands diabetes.
Not sure how Mike put the deal together but it’s a great one for MannKind.
The company is headed in the right direction it will eventually have a presidents internationally that will be driven through the addition of Dr. David Kendall.
That is why Sales have been shifted to Medtronic world wide. Mazor responsible for R&D and production.
This shift started to take place in October or November. Medtronic will have sales force trained and in place during Q1 or Q2 18.
Remember Mazor didn’t have a big sales staff.
Great things in the future.
While one would think that the GE investment in Chek is a good thing. GE is a mess and perhaps the reason Chek is struggling as who knows what the GE commitment will be moving forward.
The new president of GE indicated last week that they might sell off different pieces of GE. Chek has dropped .10 since that announcement.
Adam Feurstein on Twitter chummed a rumor about 10:00 AM. On a big Bio buying MannKind for the Insulin whistle.
He is not to be trusted and has never supported MannKind. He has worked hard to destroy the company and its equity as he has done with many Bio companies.
5 Big Biotech Stocks To Buy In 2018
Nice @mannkindcorp mentioned in same article as $CELG $AMGN $LGND $INCY 5 Biotech stocks to buy in 2018
like this guy's #4 Pick...
At least one of these biotech stocks should appeal to every investor.
By Aaron Levitt, InvestorPlace Contributor
https://investorplace.com/2018/01/5-big-biotech-stocks-buy-2018/#.Wl-7qSzrt9A
Looking for the archetype “lotto” ticket biotech stock? Then MannKind Corporation (NASDAQ:MKND) is it.
MannKind has just one product — Afrezza. The drug is an inhalable insulin used to treat diabetes. It could be a miracle cure for those suffering from the disease. Things haven’t turned out well for MKND over the years, however.
Prescriptions for the drug continue to come in well under expectations, and revenues from these written prescriptions have been paltry at best. That’s a problem when you are running low on cash and have some pretty decent debts on your balance sheet.
But there have been some positives lately — like a label ruling update from the FDA and the potential for Afrezza to be covered by insurance for some patients. The hope is that these positives, as well as higher scripts, will happen before MannKind runs out of cash. If and when that does, MKND should pop much higher.
At $2.50 per share, MKND stock is really a lotto ticket. But it may be worth it for investors looking for to add some risk to their portfolios.
What does Leafly say about it.
I own it at $1.29 and bought it as a flyer about 10 months ago. You have to have a few speculative stock in addition to some really fine winners. You use the spec for fun and you occasionally hit one big.
Stock Institutional Ownership and Shareholders
Security CVRS / Corindus Vascular Robotics, Inc. (218730109)
President and CEO Toland Mark J
Institutional Owners 58
Institutional Shares 91,492,877
Outstanding Shares 187,301,161 (as of 2017-09-30)
Institutional Value $ 121,326,000 USD
Corindus Vascular Robotics, Inc. (AMEX:CVRS) has 58 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 91,492,877 shares. Largest shareholders include Koninklijke Philips Nv, HealthCor Management, L.P., Consonance Capital Management LP, Hudson Executive Capital LP, Fmr Llc, BlackRock Inc., Vanguard Group Inc, Northern Trust Corp, State Street Corp, and Essex Investment Management Co Llc.
Here is a good SPEC stock:
Take a look at this company its about ready to start the move up. They just get CE approval and now working with GE in US trials. Check-Cap or CHEK.....
They will do a Super Bowl ad. Too many eyes watching the commercials.
They do seem to be making some progress forward. This was from early December
http://ir.check-cap.com/2017-12-05-Check-Cap-Announces-Advancement-in-GE-Healthcare-Manufacturing-Collaboration
With this CE approval Can they start marketing the product.
https://www.streetinsider.com/dr/news.php?id=13673910
Where did you see they received CE approval
Holiday weekend he probably went from the JPM 2018 Healthcare program in SFO to Denmark for a bit of R & R.
Pope better educate himself on sales. He needs a sales and marketing partner this company will die in the next 48 months. He can’t bring the product to market as he doesn’t have the sophistication and marketing skills needed to sell the product.
Lol. Dialogue helps all of us to understand the investments in their potential. So hood if one has a closed mind to looking at all the competitors of a particular company to understand the marketplace
A lot of positives will happen in 2018 for right aid. They sit stagnant for over 24 months without a plan during the Walgreens tie up.
Management gave a clearer picture earlier this week at J.P. Morgan 2018 healthcare.
Based on the slide deck they presented the narrative they were on track to do well in 2018. While we may not see the positive upside till the fourth quarter know it will happen.
Take a look at the slide deck and listen to the presentation and you can determine for yourself the direction this company will be heading this year.
https://fintel.io/doc/www.sec.gov/Archives/edgar/data/84129/000114420418001914/tv483113_8k.htm
Do you think they will buy an advertisement for moviepass during the Super Bowl
You have a great idea. I do like to see a little company take off but I don’t think this one can get over the hump with the current management team.
Yep this is not a stock that should even be on a penny site like IHUB....
I guess that he and Warren Buffett will lose together. I’m not smart enough about buying something that I can’t actually posses and it resides with who know? Somewhere in the cloud.
The IRS and SEC are just know wondering about the smoke and mirrors of Crypto so I guess we will see.
Do the bad guys trade in Crypto? Isis or the Hezbellah ? Nobody knows who they are dealing with and if their money is secure.
This will be one hell of a bubble one day.
Should have bought a week ago Monday when it was $23.00 per share. Love to get in but will wait for the next pullback.
Heico is the real deal. Great chart over 7 years.
Pretty pitiful when you compare the competition sales. 2 sales wow! They won’t make it.
Look at Mazor and their partner ship with Medtronic’s. My investment grew from about $34.00 per share to $60.00 today. Only possible because of having a great partner.
Trans needs a partner in the worst way.
I think you need to compare and contrast all products in the field.
Based on the presentation that I heard today at JPM 2018 Healthcare ISRG will not be worried about Trans for at least 30 years if Trans even makes it. I hope that Pope went to the ISRG presentation today and shook the hand of the CEO and said I have a bolt on product I could sell you.
As I have said many times with our a well oiled sales and marketing team TransEnterix will not make it very long.
Hopefully if the plan is executed correctly the value will be about $6.00 on 12/31/2018
JP Morgan 2018 Healthcare presentation is the game changer for Rite Aid. The company presented their plan going forward and I would encourage you to take the time and listen to it. You can sign in and hear the 24 minute long call.
Below are the slides they filed with the SEC of their presentation. They HAVE A PLAN.... GOING FORWARD THEY HAVE A PLAN.
You can read the slides on this link.
https://fintel.io/doc/www.sec.gov/Archives/edgar/data/84129/000114420418001914/tv483113_8k.htm
Rite Aid was in a state of limbo for 24 months going in circles. Now they will move forward. You can read for yourself how they are going to get the PPS moving if they implement according to the plan.
They will be an attractive target for a Advocate investor who sees the potential or for that matter AMAZON. Don’t think that Amazon doesn’t want a bite of this apple.
The have a lot of customers who can add to to the 75 Million Amazon customers.
PPS on 12/31/2018 minimum of $6.00
We will see shortly if they can move the company forward.
Actually Mazor Robotics has been went from $24.00 to 61.00 in 12 months. It’s an Israeli company. Medtronic’s now owns 20% of them.
Some of the folks at Chek had ties to Mazor and to PillCam which I think Medtronic’s purchased.
They seem to have a formula for splits.
There is some kind of stock manipulation going on with sprint and I believe that Masa Son is behind it.
With Masa Son Sprint will be 5.00
Correct they are concerned about an activist investor or several attacking. LIke the effective date. They might already be in play.
Rite Aid is a cheap attractive target for a shark activist investor. Here is a good list of some of the known suspects.
https://www.carriedin.com/activist-investors/
The rights deal with the date of Jan 16 is a good deal for long shareholders especially since it deals with hostile take over which at today’s share price is an easy. Notice the 5% clause.
A lot of sharks are swimming the sea looking to take a position under the darkness of the cheap price. Now they have at least installed a gatekeeper to prevent waking up one morning with a new 5% or more holder of shares.
You might even see somebody step forward prior to Jan 16th if that happened then share prices would steadily rise and we would know the company is in play.
Time will tell but we all should be ok long term.